Similar Suvival, Tolerability For Adjuvant Chemotherapy, Radiotherapy in Gastric Cancer
the Cancer Therapy Advisor take:
A recently conducted trial entitled The Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) sought to determine if the inclusion of radiotherapy with adjuvant chemotherapy improved the rate of disease-free survival in patients with D2-resected gastric cancer.
The research was conducted between November 2004 and April 2008 and 458 patients with gastric cancer who had a D2 lymph node dissection were randomly assigned to received either six cycle of adjuvant chemotherapy with capecitabine and cisplatin or to two cycle of capecitabine and cisplatin followed by chemoradiotherapy and then two cycle of capecitabine and cisplatin.
The researchers found that after 7 years of follow-up, disease-free survival rates remained similar between the two groups (hazard ratio [HR], 0.740; 95% CI, 0.520,1.050; P=0.0922).
Overall survival was also determined to be similar between the treatment groups (HR, 1.130; 95% CI, 0.775,1.647; P=0.5272). Subgroup analyses were conducted and they indicated that chemoradiotherapy was shown to significantly improve disease free survival in patients with node-positive disease and with intestinal-type GC.
The researchers conclude that in patients with D2-resected gastric cancer adjuvant chemotherapy and chemoradiotherapy are equally tolerated and able to prevent the relapse of disease. Due to the findings in regard to certain subsets of patients, additional research is underway in patients with node-positive D2-resected gastric cancer.
Inclusion of radiotherapy with adjuvant chemotherapy improved the rate of survival in D2-resected gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma
- Assays May Help Researchers Discover Factors Underlying Immunotherapy Response
- Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
- Olaparib Maintenance Prolongs PFS Compared With Placebo in Newly Diagnosed Advanced Ovarian Cancer
- Cabozantinib Effective Regardless of PD-L1 Expression in RCC